Merck Wins Hepatitis C Patent Row with Gilead

A federal jury in California has ruled in favour of US drug maker Merck in a high-profile patent dispute with rival Gilead Sciences over sofosbuvir, the active ingredient in a new blockbuster hepatitis C treatment.

The unanimous ruling on Mar. 22 declared Merck’s patents were valid and came a month after a federal judge ruled that Gilead’s hepatitis C drugs Solvadi and Harvoni infringed Merck’s intellectual property.

Sofosbuvir is the active ingredient in Solvadi and Harvoni which were launched in 2013 and 2014, respectively, becoming blockbusters overnight.

The court fight started in 2013 when Merck staked a claim for 10% of Gilead’s earnings because sofosbuvir infringed two patents that cover related compounds. Gilead filed the lawsuit in 2013, seeking for Merck’s patents to be declared invalid.

Merck is now seeking more than $2 billion in damages as well as a 10% royalty on sales of the two drugs which generated more than $19 billion in global sales for Gilead last year, accounting for nearly two-thirds of its total 2015 revenue.

“The jury’s verdict accurately reflects the evidence in this case,” said Merck which won US approval in January this year for its own hepatitis C drug, Zepatier.

Gilead responded by saying it was disappointed by the verdict and that there were a number of remaining issues that had to be decided by the judge and jury. It is expected to appeal the ruling.

Merck had been a dominant manufacturer of hepatitis C treatments until Gilead’s drugs were approved. Those drugs, as well as Merck’s and new ones from rival firms, have transformed treatment for the liver disease.

The new therapies cure about 95% of patients in eight to 12 weeks compared with the older versions that required a year of treatment yet barely cured half of patients.

Company

Logo:

Merck & Co

126 East Lincoln Avenue
07065 Rahway
US

Company contact







Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.